Boundless Bio Stock
Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Sign up today and learn more about Boundless Bio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Boundless Bio Stock
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
Funding History
September 2019 | $46.4M |
---|---|
April 2021 | $105M |
Management
Chief Executive Officer & President
Zachary Hornby
Director and Co-Founder
Benjamin Cravatt
Chairman & Co-Founder
Jonathan Lim
Chief Technology Officer
Jason Christiansen
VP, Precision Medicine
Peter Krein
Board Member
Jakob Loven
Co-Founder
Keith Lenden
VP, Program Team Leadership and Strategic Alliances
Amy Berkley
Press
sdbj - Mar, 19 2024
Boundless Bio IPOs ecDNA Platformsandiegouniontribune - Mar, 8 2024
Startup Boundless Bio files to go public — San Diego’s first life science IPO of 2024fiercebiotech - Mar, 7 2024
Boundless Bio bumps IPO market back to life after sleepy few weeksgenengnews - Jan, 19 2024
Top 10 U.S. Biopharma Clustersfiercebiotech - Jan, 19 2024
FDA's Peter Marks doesn't plan to retire soon—Chutes ...